Nanobiotix 향후 성장

Future 기준 점검 5/6

Nanobiotix은 연간 수입과 매출이 각각 55.6%와 20.9% 증가할 것으로 예상되고 EPS는 연간 55.7%만큼 증가할 것으로 예상됩니다.

핵심 정보

55.6%

이익 성장률

55.68%

EPS 성장률

Biotechs 이익 성장	58.1%
매출 성장률	20.9%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	03 Jun 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Jun 26

NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects

Analysts have raised their fair value estimate for Nanobiotix from €45.00 to €60.00, citing recent price target increases and supportive efficacy data from updated Phase 2 CONVERGE study results. Analyst Commentary Recent Street research on Nanobiotix reflects a cluster of higher price targets following updated efficacy data from the Phase 2 CONVERGE study.

새로운 내러티브 • Apr 30

Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential

Catalysts About Nanobiotix Nanobiotix develops nanoparticle based drug candidates intended to improve the effectiveness of existing cancer treatments such as radiotherapy and complex systemic therapies. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Apr 16

Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment

Catalysts About Nanobiotix Nanobiotix develops nanotechnology based therapies designed to work alongside existing cancer treatments such as radiotherapy. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Apr 01

Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech

Catalysts About Nanobiotix Nanobiotix is a biotechnology company focused on nanoscale therapies designed to work with existing treatments such as radiotherapy and complex biologic drugs. What are the underlying business or industry changes driving this perspective?

분석 기사 • Jan 31

New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)

Nanobiotix S.A. ( EPA:NANO ) shareholders will have a reason to smile today, with the analysts making substantial...

분석 기사 • Mar 14

Risks Still Elevated At These Prices As Nanobiotix S.A. (EPA:NANO) Shares Dive 27%

Nanobiotix S.A. ( EPA:NANO ) shareholders won't be pleased to see that the share price has had a very rough month...

분석 기사 • Nov 28

Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%

To the annoyance of some shareholders, Nanobiotix S.A. ( EPA:NANO ) shares are down a considerable 26% in the last...

분석 기사 • Jun 29

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The Nanobiotix S.A. ( EPA:NANO ) share price has fared very poorly over the last month, falling by a substantial 27...

분석 기사 • May 14

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

Nanobiotix S.A. ( EPA:NANO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...

분석 기사 • Apr 26

이익 및 매출 성장 예측

ENXTPA:NANO - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	88	29	77	56	6
12/31/2027	55	3	8	-12	7
12/31/2026	44	-10	-30	-23	7
12/31/2025	33	-24	-34	-33	N/A
9/30/2025	21	-38	-33	-32	N/A
6/30/2025	10	-52	-32	-31	N/A
3/31/2025	1	-60	-26	-25	N/A
12/31/2024	-7	-68	-20	-20	N/A
9/30/2024	18	-51	-11	-10	N/A
6/30/2024	42	-33	-2	-1	N/A
3/31/2024	39	-37	-7	-7	N/A
12/31/2023	36	-40	-13	-12	N/A
9/30/2023	21	-49	-25	-25	N/A
6/30/2023	7	-59	-37	-37	N/A
3/31/2023	6	-58	-37	-37	N/A
12/31/2022	5	-57	-37	-37	N/A
9/30/2022	4	-50	-35	-35	N/A
6/30/2022	3	-43	-33	-32	N/A
3/31/2022	3	-45	-31	-31	N/A
12/31/2021	3	-47	-30	-30	N/A
9/30/2021	2	-45	-30	-30	N/A
6/30/2021	2	-43	-30	-30	N/A
3/31/2021	2	-39	-29	-29	N/A
12/31/2020	2	-34	-28	-28	N/A
9/30/2020	2	-41	-31	-30	N/A
6/30/2020	2	-48	-33	-33	N/A
3/31/2020	2	-49	-38	-37	N/A
12/31/2019	3	-51	-43	-41	N/A
9/30/2019	3	-46	N/A	-37	N/A
6/30/2019	3	-42	N/A	-33	N/A
3/31/2019	3	-36	N/A	-30	N/A
12/31/2018	3	-30	N/A	-26	N/A
9/30/2018	4	-28	N/A	-24	N/A
6/30/2018	4	-27	N/A	-22	N/A
3/31/2018	4	-26	N/A	-22	N/A
12/31/2017	4	-26	N/A	-21	N/A
9/30/2017	4	-25	N/A	-20	N/A
6/30/2017	4	-24	N/A	-19	N/A
3/31/2017	5	-23	N/A	-19	N/A
12/31/2016	5	-22	N/A	-18	N/A
9/30/2016	5	-21	N/A	-19	N/A
6/30/2016	5	-19	N/A	-20	N/A
3/31/2016	5	-18	N/A	-19	N/A
12/31/2015	4	-17	N/A	-17	N/A
9/30/2015	4	-15	N/A	-15	N/A
6/30/2015	3	-13	N/A	-12	N/A

애널리스트 향후 성장 전망

수입 대 저축률: NANO 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: NANO (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: NANO 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: NANO 의 수익(연간 20.9%)이 French 시장(연간 5.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: NANO 의 수익(연간 20.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: NANO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/06/28 02:52
종가	2026/06/26 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Nanobiotix S.A.는 18명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Philippa Gardner	Edison Investment Research
Jonathan Miller	Evercore ISI
Emmanuel Parot	Gilbert Dupont

Nanobiotix 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 16% to €38.10

Consensus revenue estimates fall by 14%

Forecast breakeven date moved forward to 2027

Consensus revenue estimates increase by 40%

Price target increased by 20% to €27.44

Consensus revenue estimates increase by 24%

Recent updates

NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects

Nanobiotix Raises US$100 Million in Oversubscribed Global Offering to Fund Oncology Programs

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €85 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of €75 million.

Price target increased by 16% to €38.10

Consensus revenue estimates fall by 14%

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix S.A., Annual General Meeting, Jun 09, 2026

Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential

Forecast breakeven date moved forward to 2027

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for Lnp-Delivered Dna Immunotherapy After Pre-Treatment with Nanoprimer Technology

Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment

Consensus revenue estimates increase by 40%

Full year 2025 earnings released: €0.50 loss per share (vs €1.44 loss in FY 2024)

New major risk - Share price stability

Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech

Nanobiotix Presents First Data From Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) In Stage 3 Inoperable Lung Cancer

Nanobiotix S.A. to Report Q4, 2025 Results on Mar 31, 2026

Price target increased by 20% to €27.44

New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)

Consensus revenue estimates increase by 24%

Forecast to breakeven in 2026

New major risk - Financial position

Price target increased by 14% to €20.08

No longer forecast to breakeven

Consensus EPS estimates upgraded to €0.43 loss

New major risk - Financial position

First half 2025 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 179%

Price target increased by 17% to €13.80

Forecast to breakeven in 2026

Nanobiotix S.A. Announces First Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients with Esophageal Cancer

New minor risk - Financial position

Price target increased by 7.5% to €12.02

Consensus revenue estimates increase by 14%

New major risk - Share price stability

Now 24% undervalued

Nanobiotix Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

Consensus EPS estimates upgraded to €0.68 loss

Nanobiotix Announces Full Results from Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results from Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by Conference Call

Nanobiotix S.A., Annual General Meeting, May 19, 2025

Consensus revenue estimates increase by 10%

New major risk - Revenue size

Nanobiotix S.A. to Report Q4, 2024 Results on Apr 02, 2025

Risks Still Elevated At These Prices As Nanobiotix S.A. (EPA:NANO) Shares Dive 27%

Nanobiotix Announces First Patient Dosed in A New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients with Stage 3 Unresectable Non-Small Cell Lung Cancer

Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%

Consensus revenue estimates fall by 40%

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

New minor risk - Profitability

Forecast to breakeven in 2026

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Consensus revenue estimates fall by 24%

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Consensus revenue estimates increase by 26%

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position